TRAF2 and cancer: A splicing variant of AIMP2 lacking exon 2 (AIMP2-DX2) correlates positively with cancer by compromising the tumor-suppressive function of native AIMP2 through competitive interactions with p53 fuse-binding protein (FBP) and TNF receptor-associated factor 2 (TRAF2) [43].